{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:18:17Z","timestamp":1788365897324,"version":"build-2803163510"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":47,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Advanced Clinician Scientist Program University Medicine Zurich UMZH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Amyloid-binding positron emission tomography (PET) tracers have emerged as a promising non-invasive tool for the diagnosis of cardiac amyloidosis (CA). This study aimed to assess the diagnostic accuracy of amyloid PET for detecting CA through a meta-analysis of diagnostic test accuracy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>PubMed, Cochrane Library, Embase, and Web of Science were searched through 16 March 2026 for studies reporting the diagnostic performance of amyloid PET for CA. The primary analysis was a bivariate random-effects (Reitsma) model yielding summary sensitivity, specificity, the summary receiver operating characteristics curve with corresponding area under the curve (AUC), and positive and negative likelihood ratios. Subgroup analyses were performed by radiotracer and by amyloid subtype. Risk of bias was assessed using QUADAS-2 and publication bias by Deeks\u2019 funnel-plot asymmetry test. Twenty studies comprising 577 patients (407 with CA, 170 controls) met inclusion criteria, covering five radiotracers (11C-PiB, 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol, and 124I-evuzamitide). In the primary bivariate model (k = 17), amyloid PET demonstrated a summary sensitivity of 0.91 (95% CI 0.83\u20130.96), specificity of 0.90 (95% CI 0.79\u20130.96), and AUC of 0.96, with low between-study heterogeneity (sensitivity I2 = 13.4%; specificity I2 = 0%). Sensitivity was high and consistent across 11C-PiB, 18F-florbetaben, 18F-florbetapir, and 124I-evuzamitide (0.96\u20131.00), with the exception of 18F-flutemetamol, which showed lower and heterogeneous sensitivity (0.70).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Amyloid PET demonstrates high sensitivity and specificity for CA detection, even though the evidence base remains limited in terms of the number and scope of available studies. Prospective multicentre studies in consecutive patients with suspected CA are required to establish its clinical role and standardize acquisition protocols.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjimp\/qyag141","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:48:04Z","timestamp":1786798084000},"source":"Crossref","is-referenced-by-count":0,"title":["Diagnostic value of positron emission tomography using amyloid-binding radiotracers for cardiac amyloidosis: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0798-6034","authenticated-orcid":false,"given":"Amely","family":"Walser","sequence":"first","affiliation":[{"name":"Departments of Nuclear Medicine and Cardiology, University Hospital Zurich , Ramistrasse 100, Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-2609-6330","authenticated-orcid":false,"given":"Konstantinos","family":"Bitos","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine and Cardiology, University Hospital Zurich , Ramistrasse 100, Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0938-3170","authenticated-orcid":false,"given":"Andreas A","family":"Giannopoulos","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine and Cardiology, University Hospital Zurich , Ramistrasse 100, Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8847-2154","authenticated-orcid":false,"given":"Aju P","family":"Pazhenkottil","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine and Cardiology, University Hospital Zurich , Ramistrasse 100, Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-3031","authenticated-orcid":false,"given":"Valerie","family":"Treyer","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine and Cardiology, University Hospital Zurich , Ramistrasse 100, Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4849-3292","authenticated-orcid":false,"given":"Martin W","family":"Huellner","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine and Cardiology, University Hospital Zurich , Ramistrasse 100, Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8064-8904","authenticated-orcid":false,"given":"Ronny R","family":"Buechel","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine and Cardiology, University Hospital Zurich , Ramistrasse 100, Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-5210","authenticated-orcid":false,"given":"Philipp A","family":"Kaufmann","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine and Cardiology, University Hospital Zurich , Ramistrasse 100, Zurich 8091 ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-726X","authenticated-orcid":false,"given":"Dominik C","family":"Benz","sequence":"additional","affiliation":[{"name":"Departments of Nuclear Medicine and Cardiology, University Hospital Zurich , Ramistrasse 100, Zurich 8091 ,","place":["Switzerland"]},{"name":"Advanced Clinician Scientist Program, University Medicine Zurich (UMZH), University of Zurich , Zurich ,","place":["Switzerland"]},{"name":"Department of Cardiology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026090211314229800_qyag141-B1","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1016\/j.jcmg.2019.07.015","article-title":"How to image cardiac amyloidosis","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026090211314229800_qyag141-B2","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2026090211314229800_qyag141-B3","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.2967\/jnumed.122.264866","article-title":"Molecular imaging of systemic and cardiac amyloidosis: recent advances and focus on the future","volume":"64","author":"Dorbala","year":"2023","journal-title":"J Nucl Med"},{"key":"2026090211314229800_qyag141-B4","doi-asserted-by":"crossref","first-page":"22695","DOI":"10.1038\/srep22695","article-title":"Comparative evaluation of p5 + 14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis","volume":"6","author":"Martin","year":"2016","journal-title":"Sci Rep"},{"key":"2026090211314229800_qyag141-B5","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.3390\/molecules20057657","article-title":"Preclinical validation of the heparin-reactive peptide p5 + 14 as a molecular imaging agent for visceral amyloidosis","volume":"20","author":"Wall","year":"2015","journal-title":"Molecules"},{"key":"2026090211314229800_qyag141-B6","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026090211314229800_qyag141-B7","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"key":"2026090211314229800_qyag141-B8","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jclinepi.2005.02.022","article-title":"Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews","volume":"58","author":"Reitsma","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"2026090211314229800_qyag141-B9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026090211314229800_qyag141-B10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"2026090211314229800_qyag141-B11","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1002\/sim.1185","article-title":"Exploring sources of heterogeneity in systematic reviews of diagnostic tests","volume":"21","author":"Lijmer","year":"2002","journal-title":"Stat Med"},{"key":"2026090211314229800_qyag141-B12","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jclinepi.2005.01.016","article-title":"The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed","volume":"58","author":"Deeks","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"2026090211314229800_qyag141-B13","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","article-title":"Improved quantification of cardiac amyloid burden in systemic light chain amyloidosis: redefining early disease?","volume":"13","author":"Cuddy","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026090211314229800_qyag141-B14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/13506129.2018.1552852","article-title":"A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement","volume":"25","author":"Manwani","year":"2018","journal-title":"Amyloid"},{"key":"2026090211314229800_qyag141-B15","first-page":"316","article-title":"[Value of (11)C-PiB PET\/MRI in the evaluation of organ involvement in primary systemic light chain amyloidosis]","volume":"43","author":"Wang","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"2026090211314229800_qyag141-B16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcmg.2014.09.018","article-title":"11C-Pittsburgh B PET imaging in cardiac amyloidosis","volume":"8","author":"Lee","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026090211314229800_qyag141-B17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET","volume":"54","author":"Antoni","year":"2013","journal-title":"J Nucl Med"},{"key":"2026090211314229800_qyag141-B18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s12350-018-1260-5","article-title":"Significance of (11)C-PIB PET\/CT in cardiac amyloidosis compared with (99 m)Tc-aprotinin scintigraphy: a pilot study","volume":"27","author":"Minamimoto","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026090211314229800_qyag141-B19","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s00259-017-3814-1","article-title":"Visualization of multiple organ amyloid involvement in systemic amyloidosis using (11)C-PiB PET imaging","volume":"45","author":"Ezawa","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026090211314229800_qyag141-B20","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","article-title":"Diagnostic accuracy of [(11)C]PIB positron emission tomography for detection of cardiac amyloidosis","volume":"13","author":"Rosengren","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026090211314229800_qyag141-B21","doi-asserted-by":"crossref","first-page":"830572","DOI":"10.3389\/fcvm.2022.830572","article-title":"Diagnostic value of (11)C-PIB PET\/MR in cardiac amyloidosis","volume":"9","author":"Bi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2026090211314229800_qyag141-B22","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","article-title":"Cardiac amyloid imaging with 18F-florbetaben PET: a pilot study","volume":"57","author":"Law","year":"2016","journal-title":"J Nucl Med"},{"key":"2026090211314229800_qyag141-B23","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","article-title":"Detection of cardiac amyloidosis with (18)F-florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy","volume":"46","author":"Kircher","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026090211314229800_qyag141-B24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","article-title":"[18f]-Florbetaben PET\/CT for differential diagnosis among cardiac immunoglobulin light chain, transthyretin amyloidosis, and mimicking conditions","volume":"14","author":"Genovesi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026090211314229800_qyag141-B25","author":"Pepe"},{"key":"2026090211314229800_qyag141-B26","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using (1)(8)F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026090211314229800_qyag141-B27","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","article-title":"Amyloid PET imaging in cardiac amyloidosis: a pilot study using (18)F-flutemetamol positron emission tomography","volume":"33","author":"Dietemann","year":"2019","journal-title":"Ann Nucl Med"},{"key":"2026090211314229800_qyag141-B28","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/13506129.2020.1760237","article-title":"Quantification of cardiac amyloid with [(18)F]flutemetamol in patients with V30M hereditary transthyretin amyloidosis","volume":"27","author":"Mockelind","year":"2020","journal-title":"Amyloid"},{"key":"2026090211314229800_qyag141-B29","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12350-020-02363-2","article-title":"(18)F-flutemetamol positron emission tomography in cardiac amyloidosis","volume":"29","author":"Papathanasiou","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"2026090211314229800_qyag141-B30","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","article-title":"Cardiac amyloid detection by PET\/CT imaging of iodine ((124)I) evuzamitide ((124)I-p5 + 14): a phase 1\/2 study","volume":"16","author":"Wall","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026090211314229800_qyag141-B31","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac amyloid quantification using (124)I-evuzamitide ((124)I-P5 + 14) versus (18)F-florbetapir: a pilot PET\/CT study","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026090211314229800_qyag141-B32","doi-asserted-by":"crossref","first-page":"102374","DOI":"10.1016\/j.nuclcard.2025.102374","article-title":"Diagnostic performance of cardiac and whole-body 124I-evuzamitide (AT-01) PET\/MRI in systemic amyloidosis","volume":"50","author":"Masri","year":"2025","journal-title":"J Nucl Cardiol"},{"key":"2026090211314229800_qyag141-B33","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","article-title":"Cardiac amyloidosis imaging with amyloid positron emission tomography: a systematic review and meta-analysis","volume":"27","author":"Kim","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"2026090211314229800_qyag141-B34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jjcc.2020.07.003","article-title":"Diagnostic performance of PET for detection of cardiac amyloidosis: a systematic review and meta-analysis","volume":"76","author":"Kim","year":"2020","journal-title":"J Cardiol"},{"key":"2026090211314229800_qyag141-B35","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12872-021-02292-z","article-title":"Diagnostic performance of CMR, SPECT, and PET imaging for the detection of cardiac amyloidosis: a meta-analysis","volume":"21","author":"Wu","year":"2021","journal-title":"BMC Cardiovasc Disord"},{"key":"2026090211314229800_qyag141-B36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00259-023-06381-3","article-title":"Positron emission tomography in the diagnosis and follow-up of transthyretin amyloid cardiomyopathy patients: a systematic review","volume":"51","author":"Tingen","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026090211314229800_qyag141-B37","doi-asserted-by":"crossref","first-page":"37731","DOI":"10.31083\/RCM37731","article-title":"Diagnostic performance of positron emission tomography in the assessment of systemic amyloidosis: a systematic review and meta-analysis","volume":"26","author":"Zhu","year":"2025","journal-title":"Rev Cardiovasc Med"},{"key":"2026090211314229800_qyag141-B38","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12350-016-0638-5","article-title":"Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)","volume":"25","author":"Pilebro","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"2026090211314229800_qyag141-B39","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2967\/jnumed.121.263033","article-title":"Independent prognostic utility of (11)C-Pittsburgh compound B PET in patients with light-chain cardiac amyloidosis","volume":"63","author":"Choi","year":"2022","journal-title":"J Nucl Med"},{"key":"2026090211314229800_qyag141-B40","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/13506129.2020.1798223","article-title":"Non-invasive detection and differentiation of cardiac amyloidosis using (99 m)Tc-pyrophosphate scintigraphy and (11)C-Pittsburgh compound B PET imaging","volume":"27","author":"Takasone","year":"2020","journal-title":"Amyloid"},{"key":"2026090211314229800_qyag141-B41","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1007\/s00259-025-07157-7","article-title":"Enhanced diagnostic and prognostic assessment of cardiac amyloidosis using combined (11)C-PiB PET\/CT and (99 m)Tc-DPD scintigraphy","volume":"52","author":"Hong","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026090211314229800_qyag141-B42","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s10554-021-02190-7","article-title":"Deep-learning-based cardiac amyloidosis classification from early acquired pet images","volume":"37","author":"Santarelli","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"key":"2026090211314229800_qyag141-B43","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s12350-021-02608-8","article-title":"Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images","volume":"29","author":"Santarelli","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"2026090211314229800_qyag141-B44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13550-018-0425-1","article-title":"(18)F-florbetaben whole-body PET\/MRI for evaluation of systemic amyloid deposition","volume":"8","author":"Baratto","year":"2018","journal-title":"EJNMMI Res"},{"key":"2026090211314229800_qyag141-B45","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/RLU.0000000000001434","article-title":"18F-florbetaben: a new tool for amyloidosis staging?","volume":"42","author":"D'Estanque","year":"2017","journal-title":"Clin Nucl Med"},{"key":"2026090211314229800_qyag141-B46","doi-asserted-by":"crossref","first-page":"e503","DOI":"10.1097\/RLU.0000000000002699","article-title":"Clinical utility of 18F-florbetaben PET for detecting amyloidosis associated with multiple myeloma: a prospective case-control study","volume":"44","author":"Seo","year":"2019","journal-title":"Clin Nucl Med"},{"key":"2026090211314229800_qyag141-B47","doi-asserted-by":"crossref","first-page":"102626","DOI":"10.1016\/j.jacadv.2026.102626","article-title":"(18)F-florbetaben PET detection of cardiac and multi-organ involvement for identifying AL and ATTR cardiac amyloidosis","volume":"5","author":"Sprauel","year":"2026","journal-title":"JACC Adv"},{"key":"2026090211314229800_qyag141-B48","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fcvm.2015.00023","article-title":"A routine PET\/CT protocol with streamlined calculations for assessing cardiac amyloidosis using (18)F-florbetapir","volume":"2","author":"Osborne","year":"2015","journal-title":"Front Cardiovasc Med"},{"key":"2026090211314229800_qyag141-B49","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1080\/13506129.2018.1467313","article-title":"Utility of the (18)F-florbetapir positron emission tomography in systemic amyloidosis","volume":"25","author":"Mestre-Torres","year":"2018","journal-title":"Amyloid"},{"key":"2026090211314229800_qyag141-B50","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s12350-021-02524-x","article-title":"Positron emission tomography for cardiac amyloidosis: timing matters!","volume":"29","author":"Singh","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"2026090211314229800_qyag141-B51","doi-asserted-by":"crossref","first-page":"102726","DOI":"10.1016\/j.nuclcard.2026.102726","article-title":"An era of precision: emerging, research, and adjunct radiotracers for nuclear imaging of cardiac amyloidosis","volume":"59S","author":"Wall","year":"2026","journal-title":"J Nucl Cardiol"},{"key":"2026090211314229800_qyag141-B52","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.jcmg.2025.01.018","article-title":"Early detection of transthyretin cardiac amyloidosis using (124)I-evuzamitide positron emission tomography\/computed tomography","volume":"18","author":"Smiley","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"12):","key":"2026090211314229800_qyag141-B53","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.jcmg.2025.07.017","article-title":"Changes in myocardial light chain amyloid burden after plasma cell therapy","volume":"18","author":"Benz","year":"2025","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["European Heart Journal - Imaging Methods and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjimp\/advance-article-pdf\/doi\/10.1093\/ehjimp\/qyag141\/70682311\/qyag141.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjimp\/article-pdf\/4\/3\/qyag141\/70682311\/qyag141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjimp\/article-pdf\/4\/3\/qyag141\/70682311\/qyag141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:31:55Z","timestamp":1788363115000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjimp\/article\/doi\/10.1093\/ehjimp\/qyag141\/8763570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjimp\/qyag141","relation":{},"ISSN":["2755-9637"],"issn-type":[{"value":"2755-9637","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,7,2]]},"article-number":"qyag141"}}